KCNRG: A Potential Drug Target and Biomarker for Neurological Psychiatric Disorders

Target Name: KCNRG

NCBI ID: G283518

KCNRG

KCNRG: A Potential Drug Target and Biomarker for Neurological Psychiatric Disorders

KCNRG, also known as KCNQ1, is a gene that has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders. The gene is located on chromosome 6 and encodes a protein known as K-type channels, which are a type of ion channel found in neuron cells.

K-type channels are involved in the regulation of electrical activity in neuronal cells, and their dysfunction has been implicated in a number of neurological and psychiatric disorders. For example, studies have suggested that individuals with certain genetic variations in the KCNQ1 gene may be at increased risk for conditions such as epilepsy, schizophrenia, and bipolar disorder.

In addition to its potential as a drug target, KCNRG has also been identified as a potential biomarker for psychiatric certain disorders. For example, studies have shown that individuals with certain genetic variations in the KCNQ1 gene may be more likely to experience symptoms of depression and anxiety.

Overall, the study of KCNRG has significant implications for the development of new treatments for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of this gene as a drug target and biomarker, and to develop effective treatments for individuals with genetic variations in the KCNQ1 gene.

Protein Name: Potassium Channel Regulator

Functions: Inhibits potassium fluxes in cells. May regulate Kv1 family channel proteins by retaining a fraction of channels in endomembranes

The "KCNRG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNRG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets